Contract analysis
Clause-by-clause risk read on any document of the firm. Pick a contract, or open any document from a matter.
Contract analysis / email-stonebridge-cp-update.eml
email-stonebridge-cp-update.eml
High · 1
Medium · 0
Standard · 2
From: "Ryan Kowalski", Associate, "Calderwood & Harkness LLP"
From: "Ryan Kowalski", Associate, "Calderwood & Harkness LLP" To: "Nathan Ostrowski", "Managing Director", "Stonebridge Credit Partners LLC" Cc: "James Prentice", Partner, "Calderwood & Harkness LLP", Partner, "Calderwood & Harkness LLP", Director, "Birchwood Capital Finance LLC", Partner, "Ironvale Credit Fund III LP", CFO, "Ardent Capital" Subject: Project Apex — Conditions Precedent Update / Commitment Letter Ref.
I hope this finds you well. Writing to provide a periodic update on the status of the cond
I hope this finds you well. Writing to provide a periodic update on the status of the conditions precedent to funding under the Senior Secured Credit Facility Commitment Letter dated March 8, 2025 (Ref. SC-2025-0312-AC) among Ardent Apex Holdings Inc., Ardent Apex Merger Sub Inc., and Stonebridge Credit Partners LLC, as lead arranger and administrative agent, in connection with the acquisition of Luminex Systems Hold
As a reminder, this relates to the $1,400,000,000 senior secured credit facility, comprisi
As a reminder, this relates to the $1,400,000,000 senior secured credit facility, comprising a $1,200,000,000 Term Loan B and a $200,000,000 Revolving Credit Facility.
Set forth below is the current status of all regulatory approvals constituting conditions
Set forth below is the current status of all regulatory approvals constituting conditions precedent to closing and funding:
(a) **HSR Act Filing.** The HSR premerger notification was filed on March 28, 2025 (Transa
Standard
⚑ Commercial term
(a) **HSR Act Filing.** The HSR premerger notification was filed on March 28, 2025 (Transaction No. HSR-20250328-4192), and the filing fee of $2,390,000 has been paid. The matter was cleared to the FTC pursuant to the DOJ/FTC clearance allocation on April 2, 2025, and the initial 30-day waiting period is set to expire on April 27, 2025. Based on communications with FTC staff and the competitive overlap in the procure
(b) **CFIUS Review.** A voluntary joint notice was filed on April 4, 2025 (Tracking No. CF
(b) **CFIUS Review.** A voluntary joint notice was filed on April 4, 2025 (Tracking No. CFIUS-2025-0087). The filing was made on the basis that Luminex Systems Inc. (the U.S. operating subsidiary) holds contracts with three U.S. federal agencies — the Department of Defense (logistics software module), the Department of Energy (procurement platform), and the GSA (enterprise license) — constituting covered transactions
(c) **Swiss Competition / SECO (Lex Koller).** A notification was filed on April 7, 2025 w
(c) **Swiss Competition / SECO (Lex Koller).** A notification was filed on April 7, 2025 with the Swiss Competition Commission and SECO (File No. 32-0973). Combined Swiss revenues exceed the CHF 100 million threshold under the Cartel Act (KartG). The matter is currently in Phase I review. Local counsel Breitfeld Hess & Partner AG (Dr. Lukas Breitfeld) is monitoring.
(d) **German Federal Cartel Office (Bundeskartellamt).** The filing was submitted on April
(d) **German Federal Cartel Office (Bundeskartellamt).** The filing was submitted on April 9, 2025 (File No. B6-34/25). Jurisdictional thresholds are met on the basis that Veltronix GmbH reported 2024 German revenue of €67,000,000 and Vectis GmbH reported German revenue of €12,000,000, with combined figures exceeding the €500 million worldwide and €25 million domestic thresholds under GWB §35. The matter is currently
(e) **EU Foreign Subsidies Regulation (FSR).** A notification was filed on April 11, 2025
(e) **EU Foreign Subsidies Regulation (FSR).** A notification was filed on April 11, 2025 (Case No. FSR.M.2025-0412). The filing was triggered on the basis that EU turnover exceeds €500 million and foreign financial contributions exceed €50 million in the aggregate, including contributions attributable to Ardent LP's limited-partner base of sovereign wealth and state-affiliated pension funds. The preliminary review p
The Merger Agreement was executed on March 24, 2025, and execution counterparts have been
The Merger Agreement was executed on March 24, 2025, and execution counterparts have been exchanged between Calderwood & Harkness and seller's counsel, Caldwell, Raines & Sheppard LLP (Patricia Okonkwo). Disclosure schedules have been delivered and are under review; Buyer's comments on the Seller's disclosure schedules have been transmitted to CRS.
The draft credit agreement has been circulated among the lending group (Stonebridge, Birch
The draft credit agreement has been circulated among the lending group (Stonebridge, Birchwood Capital Finance LLC, and Ironvale Credit Fund III LP). We would expect comments from the co-lenders to be consolidated and returned at your convenience (see request below).
The draft Guarantee and Collateral Agreement is being finalized and contemplates a first-p
The draft Guarantee and Collateral Agreement is being finalized and contemplates a first-priority lien on substantially all assets of Luminex Holdings and its domestic subsidiaries, together with a 65% pledge of first-tier foreign subsidiary equity.
The Intercreditor Agreement between Stonebridge (as senior representative) and Crestline M
The Intercreditor Agreement between Stonebridge (as senior representative) and Crestline Mezzanine Partners II LP (as subordinated representative) is in advanced draft form. We can confirm that the $300,000,000 subordinated notes are contractually subordinated to the Senior Secured Credit Facility.
**3. Other Conditions Precedent — Status Summary**
**3. Other Conditions Precedent — Status Summary**
- **R&W Insurance:** The representations and warranties insurance policy is being bound wi
- **R&W Insurance:** The representations and warranties insurance policy is being bound with Grandview Specialty Insurance Company (Policy No. GSI-RWI-2025-04821) through Ashbury Risk Advisors LLC (Philip Navarro). The policy carries a $420,000,000 policy limit with a $14,000,000 retention (50/50 buyer/seller split) and an estimated premium of $8,400,000.
- **Escrow Agreement:** The Escrow Agreement with Continental Fiduciary Trust Company is s
Standard
⚑ Commercial term
- **Escrow Agreement:** The Escrow Agreement with Continental Fiduciary Trust Company is substantially finalized (Escrow Account Ref. CFT-ESC-2025-7894). The escrow amount is $140,000,000 (5% of deal value), to be held for 18 months.
- **Solvency Certificate:** The form of solvency certificate to be delivered by the CFO of
- **Solvency Certificate:** The form of solvency certificate to be delivered by the CFO of the surviving corporation at closing has been prepared and circulated to the Ardent team for review.
- **Equity Commitment Letter:** The Ardent Capital Partners III LP equity commitment of $6
- **Equity Commitment Letter:** The Ardent Capital Partners III LP equity commitment of $695,980,000 is in place.
- **Co-Investment Commitments:** Co-investment agreements have been executed with Northval
- **Co-Investment Commitments:** Co-investment agreements have been executed with Northvale Sovereign Holdings Ltd. ($200,000,000) and Summit Ridge Capital Partners LP ($100,000,000).
- **Management Rollover:** Rollover agreements for management participants (aggregate roll
- **Management Rollover:** Rollover agreements for management participants (aggregate rollover of approximately $405,020,000) are being finalized. Key participants include Dr. Stefan Kessler (CEO, $142,800,000 rollover), Annelise Gruber (CFO, $58,800,000 rollover), and Dr. Markus Vogt (CTO, $58,520,000 rollover).
- **Legal Opinion / 10b-5 Letter:** Calderwood & Harkness's legal opinion and 10b-5 negati
- **Legal Opinion / 10b-5 Letter:** Calderwood & Harkness's legal opinion and 10b-5 negative assurance letter (if required by the lending group) are in preparation and will be in deliverable form prior to closing.
The target estimated closing remains Q3 2025 (July–August 2025), subject to regulatory app
The target estimated closing remains Q3 2025 (July–August 2025), subject to regulatory approval timelines. The most significant variable is the anticipated HSR Second Request process and completion of the CFIUS review. The Outside Date under the Merger Agreement is September 10, 2025, with a three-month extension available (to December 10, 2025) if the sole unsatisfied condition at that time is regulatory approval. B
We would appreciate it if Stonebridge and the co-lenders (Birchwood and Ironvale) could pr
We would appreciate it if Stonebridge and the co-lenders (Birchwood and Ironvale) could provide consolidated comments on the draft credit agreement at their earliest convenience. Calderwood & Harkness will provide further updates following the expiration of the HSR initial waiting period on April 27, 2025, and upon receipt of any communication from CFIUS.
Please let us know if it would be helpful to arrange a call with the broader deal team — i
Please let us know if it would be helpful to arrange a call with the broader deal team — including James Prentice, the Ardent Capital team, and the lending syndicate — to discuss any open items. We are also maintaining a Regulatory Conditions & Timetable Tracker internally and can share a redacted version if that would be useful.
Thank you, and please don't hesitate to reach out with any questions.
Thank you, and please don't hesitate to reach out with any questions.
Ryan Kowalski
Ryan Kowalski Associate, Mergers & Acquisitions Calderwood & Harkness LLP 7 Times Square New York, NY 10036 Direct: (212) 555-4738 rkowalski@calderwoodharkness.com Calderwood & Harkness Matter No. 1001-00004
*CONFIDENTIALITY NOTICE: This email and any attachments are for the exclusive and confiden
High
⚑ Non-compete / exclusivity restraint
*CONFIDENTIALITY NOTICE: This email and any attachments are for the exclusive and confidential use of the intended recipient. This communication may contain information that is privileged, confidential, and exempt from disclosure under applicable law, including attorney-client privilege and/or work product doctrine. If you are not the intended recipient, any use, dissemination, distribution, or copying of this commun